Ken Griffin Anavex Life Sciences Corp. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $88,776 - $152,064	21,600 Added 56.54%	59,800 $339,000
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $25,764 - $38,152	-7,600 Reduced 16.59%	38,200 $161,000
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $434,980 - $645,300	-95,600 Reduced 67.61%	45,800 $233,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $73,584 - $145,270	14,600 Added 11.51%	141,400 $1.32 Million
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $43,230 - $61,841	6,600 Added 5.49%	126,800 $830,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $543,860 - $674,500	71,000 Added 144.31%	120,200 $977,000
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $1.08 Million - $1.53 Million	-129,900 Reduced 72.53%	49,200 $421,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $463,590 - $874,458	60,600 Added 51.14%	179,100 $1.66 Million
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $119,260 - $172,324	-13,400 Reduced 10.16%	118,500 $1.22 Million

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $944M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.